Agilent Corp (A) Long-Term Debt to Capital Ratio

Symbol and logo of brand Agilent Technologies (A)

Agilent Technologies (A) new management is seamlessly continuing the strategic development vector while maintaining the stability of corporate processes. This chart of the long-term debt-to-equity ratio currently reflects a level of 0.54. The business generates revenue from the sale of diagnostic instruments and components for various industries, which minimizes sector-specific risks. The manufacturer's flawless reputation for precision equipment guarantees global recognition within the scientific community.

Agilent Technologies, Inc. (A): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026
Original product of Agilent

This ratio compares long-term debt obligations to equity, revealing the extent to which financial stability depends on external borrowings amid changes in the market value of shares. The trend of the long-term debt-to-equity ratio reflects the strategy of Agilent Technologies (A) for financing the development of high-precision laboratory equipment, where the balance between cheap debt and equity determines the pace of technological upgrades in genetics and ecology.

Analysis of competing companies

Long-Term Debt to Capital Quest Diagnostics Inc.|Long-Term Debt to Equity Illumina Corp (ILMN)|Exact Sciences Inc. - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RVTY (Revvity, Inc.)|Long-Term Debt to Capital bio-rad.com BIO|NNNN - Long-Term Debt to Equity|SHC: Long-Term Debt to Equity|QDEL (QuidelOrtho Corp) - Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital OPKO Health Corp. (OPK)|Long-Term Debt to Equity CareDx Inc|maravai.com (MRVI) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital FLGT|Ratio of Long-Term Indebtedness to Capital Standard BioTools Inc|Long-Term Debt to Equity Cytek Bio CTKB|Ratio of Long-Term Indebtedness to Capital OraSure Corp (OSUR)|Exagen Diagnostics - Long-Term Debt to Capital|MDXH - Long-Term Debt to Capital|LUCD: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Prenetics PRE|IMDX (Insight Molecular Diagnostics, Inc.) - Long-Term Debt to Capital|Trinity Biotech Corp (TRIB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ProPhase Labs, Inc. (PRPH)|Long-Term Debt to Equity AIMD (ainos.com)|Long-Term Debt to Capital CODX (Co-Diagnostics)|Heart Test Laboratories, Inc. (HSCS) - Long-Term Liabilities to Capital|BMRA - Long-Term Debt to Equity|CDIO (Cardio Diagnostics) - Long-Term Debt to Capital Ratio|VRAX (Virax Biolabs Group) - Long-Term Debt to Equity Ratio|BJDX: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio AWH|AXDX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CNTG (CENTOGENE, N.V.)|Long-Term Loans to Capital Ratio ENZ|Long-Term Debt to Capital FRES (Fresh2 Group)|Genetic Technologies Ltd (GENE) - Long-Term Liabilities to Capital|23andMe - Long-Term Debt to Capital|Psychemedics Corp. (PMD) - Long-Term Debt to Equity Ratio